



**Technology:** Insulin glargine is a long-acting recombinant human insulin analog that helps to control blood sugar levels in patients with diabetes.

## Insulin Glargine Timeline



## Insulin Glargine Challenged Claim Types in IPR and Litigation\*



\*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

# Spotlight On: Insulin Glargine

February 28, 2019

|           | <i>Sanofi v. Eli Lilly</i><br>1:14-cv-00113 (D. Del.)<br>Settled | <i>Sanofi v. Eli Lilly</i><br>1:14-cv-00884 (D. Del.)<br>Settled | <i>Sanofi v. Merck</i><br>1:16-cv-00812 (D. Del.)<br>Stipulated dismissal | <i>Sanofi v. Merck</i><br>2:17-cv-05914 (D.N.J.)<br>Stipulated dismissal | <i>Sanofi v. Mylan</i><br>2:17-cv-09105 (D.N.J.)<br>Ongoing | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2017-01526<br>FWD (All instituted claims unpatentable) | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2017-01528<br>FWD (All instituted claims unpatentable) | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2018-01670<br>Awaiting institution decision | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2018-01675<br>IPR2018-01676<br>Awaiting institution decision | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2018-01677<br>Terminated prior to institution decision;<br>Refiled as IPR2019-00122 | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2018-01678<br>IPR2018-01679<br>Awaiting institution decision |
|-----------|--|--|---|--|---|--|--|---|--|---|--|
| 7,476,652 | x  | x  | x   | x  | x   | x  |  |   |  |   |  |
| 7,713,930 | x  | x  | x   | x  | x   |  | x  |   |  |   |  |
| 7,918,833 |  | x  | x   |  | x   |  |  |   |  |   |  |
| 8,512,297 |  | x  | x   |  | x   |  |  |   |  |   |  |
| 8,556,864 | x  | x  | x   |  | x   |  |  |   |  |   |  |
| 8,603,044 | x  | x  | x   |  | x   |  |  |   | x  |   |  |
| 8,679,069 | x  | x  | x   |  | x   |  |  | x   |  |   |  |
| 8,992,486 |  |  | x   |  | x   |  |  |   |  | x   | x  |
| 9,011,391 |  |  | x   |  | x   |  |  |   |  |   |  |
| 9,233,211 |  |  | x   |  | x   |  |  |   |  | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2018-01680<br>IPR2018-01682<br>IPR2018-01696<br>Awaiting institution decision       | <i>Biocon &amp; Mylan v. Sanofi</i><br>IPR2018-01684<br>Awaiting institution decision                  |
| 9,408,979 |  |  |   |  | x   |  |  |   |  |   |  |
| 9,457,152 |  |  | x   |  |   |  |  |   |  |   |  |
| 9,486,587 |  |  | x   |  |   |  |  |   |  |   |  |
| 9,526,844 |  |  | x   |  | x   |  |  |   |  | x   |  |
| 9,533,105 |  |  | x   |  | x   |  |  |   |  |   |  |
| 9,561,331 |  |  |   |  | x   |  |  |   |  |   |  |
| 9,592,348 |  |  | x   |  |   |  |  |   |  |   |  |
| 9,604,008 |  |  | x   |  | x   |  |  |   |  |   | x  |
| 9,604,009 |  |  |   |  | x   |  |  |   |  |   |  |
| 9,610,409 |  |  |   |  | x   |  |  |   |  |   |  |
| 9,623,189 |  |  |   |  | x   |  |  |   |  |   |  |